<code id='9E3864CE22'></code><style id='9E3864CE22'></style>
    • <acronym id='9E3864CE22'></acronym>
      <center id='9E3864CE22'><center id='9E3864CE22'><tfoot id='9E3864CE22'></tfoot></center><abbr id='9E3864CE22'><dir id='9E3864CE22'><tfoot id='9E3864CE22'></tfoot><noframes id='9E3864CE22'>

    • <optgroup id='9E3864CE22'><strike id='9E3864CE22'><sup id='9E3864CE22'></sup></strike><code id='9E3864CE22'></code></optgroup>
        1. <b id='9E3864CE22'><label id='9E3864CE22'><select id='9E3864CE22'><dt id='9E3864CE22'><span id='9E3864CE22'></span></dt></select></label></b><u id='9E3864CE22'></u>
          <i id='9E3864CE22'><strike id='9E3864CE22'><tt id='9E3864CE22'><pre id='9E3864CE22'></pre></tt></strike></i>

          explore

          explore

          author:fashion    Page View:534
          Andrew Witty, Chief Executive Officer of UnitedHealth Group, testifies at a Senate Finance Committee hearing examining cyber attacks.-- health tech coverage from STAT
          UnitedHealth Group CEO Andrew Witty said the company was beginning to see a “disturbance” in its Medicaid medical costs. Jacquelyn Martin/AP

          You’re reading the web version of Health Care Inc., STAT’s weekly newsletterfollowing the flow of money in medicine. Sign upto get it in your inbox every Monday.

          What’s next for Risant?

          Kaiser Permanente grabbed everyone’s attention last year when it said it was creating Risant Health, a new and vague entity that acquired Geisinger and had plans to scoop up at least four more health systems that are focused on “value-based care.”

          advertisement

          Well, nothing has happened since then, at least publicly. Instead, everyone has been playing the parlor game of guessing who those next systems could be. There are some rumblings that the next deal could be announced in the near future. After reading some recent hospital financial reports, it’s clear there are a handful of systems that mirror Geisinger’s shaky trajectory and could find themselves in Kaiser’s crosshairs.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more
          David Liu startup to focus on CRISPR delivery
          David Liu startup to focus on CRISPR delivery

          DavidLiu(left)withreporterJonathanWosenatthe2022STATSummit.STATDavidLiu,theBroadInstitutebiochemistb

          read more
          New air purifier tech could be key to improving indoor air quality
          New air purifier tech could be key to improving indoor air quality

          AdobeUntiltheearly20thcentury,Americaregularlyexperiencedbrutallydestructiveurbanfires.Conflagration

          read more

          'A game

          BillSikes/APOnMonday,VertexPharmaceuticalssecuredapprovalofanewcysticfibrosisdrug.MargotClevelandbou